Estimaciones de analistas de Wall Street para Nanobiotix S.A. (NBTX): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-09-29 | $-0.48 | ||
| 2026-03-31 | $-0.46 | $0.30 | -250.7% |
| 2025-09-30 | $-0.13 | $-0.25 | +45.9% |
| 2025-04-02 | $-1.01 | $-0.62 | -63.5% |
| 2024-11-12 | $-0.50 | $-0.51 | +2.5% |
| 2024-04-24 | $-0.33 | $-0.83 | +60.4% |
| 2023-11-13 | $-0.87 | $-0.59 | -47.6% |
| 2023-03-28 | $-0.95 |
Ratios de valoración
| Precio / Valor contable | -15.69 |
| EV / EBITDA | -140.35 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $5.4M | $3.7M | $3.5M | $2.5M | $2.3M | $2.6M | $4.8M | $36.2M | -$7.2M | $29.6M |
| Coste de Ventas | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | $5.4M | $3.7M | $3.5M | $2.5M | $2.3M | $2.6M | $4.8M | $36.2M | -$7.2M | $29.6M |
| I+D | $16.9M | $17.7M | $20.9M | $30.4M | $24.3M | $30.4M | $32.6M | $38.4M | $40.5M | $23.1M |
| Generales y Administrativos | $10.4M | $11.3M | $12.7M | $18.9M | $14.6M | $19.4M | $17.9M | $22.0M | $20.5M | $20.2M |
| Gastos Operativos | $27.3M | $29.0M | $33.5M | $49.3M | $38.8M | $55.2M | $51.5M | $63.0M | $61.2M | $40.5M |
| Beneficio Operativo | -$21.9M | -$25.3M | -$30.1M | -$46.8M | -$36.4M | -$52.6M | -$46.7M | -$26.8M | -$68.4M | -$10.8M |
| EBITDA | -$21.4M | -$24.8M | -$29.4M | -$45.0M | -$34.9M | -$45.6M | -$44.2M | -$23.7M | -$67.7M | -$12.1M |
| Gastos por Intereses | $102203 | $108367 | $847000 | $4.8M | $333000 | $699490 | $5.8M | $8.0M | $8.1M | $10.4M |
| Beneficio Antes de Impuestos | -$21.8M | -$26.1M | -$30.3M | -$50.9M | -$33.6M | -$47.0M | -$57.0M | -$39.6M | -$68.0M | -$24.0M |
| Impuestos | $90425 | 0 | 0 | $3000 | $9000 | $5000 | $10000 | $120000 | $101000 | $3000 |
| Beneficio Neto | -$21.9M | -$26.1M | -$30.3M | -$50.9M | -$33.6M | -$47.0M | -$57.0M | -$39.7M | -$68.1M | -$24.0M |
| BPA | $-1.43 | $-1.50 | $-1.52 | $-2.35 | $-1.38 | $-1.35 | $-1.64 | $-1.08 | $-1.44 | $-0.50 |
| BPA Diluido | $-1.43 | $-1.50 | $-1.52 | $-2.35 | $-1.38 | $-1.35 | $-1.64 | $-1.08 | $-1.44 | $-0.50 |
| Acciones en Circulación (Diluidas) | $15.3M | $17.5M | $19.6M | $21.6M | $24.4M | $34.7M | $34.9M | $36.9M | $47.3M | $47.8M |
Precio
| Precio | $34.40 |
| Capitalización | $1.7B |
| Bolsa | NASDAQ |
| País | FR |
Empresas relacionadas: ABUS · EYPT · GHRS · KURA · LENZ · PROK · RZLT
Explorar sector: Healthcare · Biotechnology
Más secciones de NBTX: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones